These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 34140296)

  • 1. A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease.
    Ryerson CJ; Corte TJ; Myers JL; Walsh SLF; Guler SA
    Eur Respir J; 2021 Dec; 58(6):. PubMed ID: 34140296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
    Hyldgaard C
    Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unclassifiable interstitial lung disease: from phenotyping to possible treatments.
    Guler SA; Ryerson CJ
    Curr Opin Pulm Med; 2018 Sep; 24(5):461-468. PubMed ID: 30004990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unclassifiable interstitial lung disease: A review.
    Skolnik K; Ryerson CJ
    Respirology; 2016 Jan; 21(1):51-6. PubMed ID: 26059704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and prognosis of unclassifiable interstitial lung disease.
    Ryerson CJ; Urbania TH; Richeldi L; Mooney JJ; Lee JS; Jones KD; Elicker BM; Koth LL; King TE; Wolters PJ; Collard HR
    Eur Respir J; 2013 Sep; 42(3):750-7. PubMed ID: 23222877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and Management of Fibrotic Interstitial Lung Diseases.
    Collins BF; Luppi F
    Clin Chest Med; 2021 Jun; 42(2):321-335. PubMed ID: 34024407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.
    Cottin V; Hirani NA; Hotchkin DL; Nambiar AM; Ogura T; Otaola M; Skowasch D; Park JS; Poonyagariyagorn HK; Wuyts W; Wells AU
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the diagnosis and classification of ILD.
    Ryerson CJ; Collard HR
    Curr Opin Pulm Med; 2013 Sep; 19(5):453-9. PubMed ID: 23872860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unclassifiable, or simply unclassified interstitial lung disease?
    O'Callaghan M; Bonella F; McCarthy C
    Curr Opin Pulm Med; 2021 Sep; 27(5):405-413. PubMed ID: 34172623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical profile of unclassifiable interstitial lung disease: Comparison with chronic fibrosing idiopathic interstitial pneumonias.
    Traila D; Oancea C; Tudorache E; Mladinescu OF; Timar B; Tudorache V
    J Int Med Res; 2018 Jan; 46(1):448-456. PubMed ID: 28758849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in the classification of fibrotic ILD.
    Bendstrup E; Maher TM; Manali ED; Wijsenbeek M
    Sarcoidosis Vasc Diffuse Lung Dis; 2015 Aug; 32 Suppl 1():4-9. PubMed ID: 26237436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of the interstitial lung disease multidisciplinary service.
    Jo HE; Glaspole IN; Levin KC; McCormack SR; Mahar AM; Cooper WA; Cameron R; Ellis SJ; Cottee AM; Webster SE; Troy LK; Torzillo PJ; Corte P; Symons KM; Taylor N; Corte TJ
    Respirology; 2016 Nov; 21(8):1438-1444. PubMed ID: 27427515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature.
    Ferri C; Manfredi A; Sebastiani M; Colaci M; Giuggioli D; Vacchi C; Della Casa G; Cerri S; Torricelli P; Luppi F
    Autoimmun Rev; 2016 Jan; 15(1):61-70. PubMed ID: 26384526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Multidisciplinary Discussion (MDD) in the Diagnosis and Management of Fibrotic Interstitial Lung Diseases.
    Ageely G; Souza C; De Boer K; Zahra S; Gomes M; Voduc N
    Can Respir J; 2020; 2020():9026171. PubMed ID: 32879642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unclassifiable interstitial lung diseases: Clinical characteristics and survival.
    Hyldgaard C; Bendstrup E; Wells AU; Hilberg O
    Respirology; 2017 Apr; 22(3):494-500. PubMed ID: 28297158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis.
    Guler SA; Ellison K; Algamdi M; Collard HR; Ryerson CJ
    Ann Am Thorac Soc; 2018 Jul; 15(7):854-863. PubMed ID: 29779392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.